BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19476859)

  • 61. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
    Soucy G; Bélanger J; Leblanc G; Sideris L; Drolet P; Mitchell A; Leclerc YE; Dufresne MP; Beaudet J; Dubé P
    J Am Coll Surg; 2008 Jun; 206(6):1116-21. PubMed ID: 18501808
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
    Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
    Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M
    Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
    Esgueva A; Siso C; Espinosa-Bravo M; Sobrido C; Miranda I; Salazar JP; Rubio IT
    J Surg Oncol; 2021 Jan; 123(1):71-79. PubMed ID: 33002230
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
    Forero-Torres A; Saleh MN; Galleshaw JA; Jones CF; Shah JJ; Percent IJ; Nabell LM; Carpenter JT; Falkson CI; Krontiras H; Urist MM; Bland KI; De Los Santos JF; Meredith RF; Caterinicchia V; Bernreuter WK; O'Malley JP; Li Y; LoBuglio AF
    Clin Breast Cancer; 2010 Aug; 10(4):275-80. PubMed ID: 20705559
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment.
    Rubio IT; Esgueva-Colmenarejo A; Espinosa-Bravo M; Salazar JP; Miranda I; Peg V
    Ann Surg Oncol; 2016 Jan; 23(1):38-43. PubMed ID: 26514120
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
    Prowell TM; Blackford AL; Byrne C; Khouri NF; Dowsett M; Folkerd E; Tarpinian KS; Powers PP; Wright LA; Donehower MG; Jeter SC; Armstrong DK; Emens LA; Fetting JH; Wolff AC; Garrett-Mayer E; Skaar TC; Davidson NE; Stearns V
    Cancer Prev Res (Phila); 2011 Dec; 4(12):1993-2001. PubMed ID: 21885816
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
    Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
    Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
    Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
    Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Does the placement of surgical clips within the excision cavity influence local control for patients treated with breast-conserving surgery and irradiation.
    Fein DA; Fowble BL; Hanlon AL; Hoffman JP; Sigurdson ER; Eisenberg BL
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1009-17. PubMed ID: 8600083
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Patterns and determinants of surgical management of screen detected breast cancer in the South-East Netherlands.
    Liebregts ME; van Riet YE; Nieuwenhuijzen GA; Rutten HJ; Duijm LE; Voogd AC
    Breast; 2013 Oct; 22(5):713-7. PubMed ID: 23352567
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    Goss PE; Ingle JN; Pritchard KI; Robert NJ; Muss H; Gralow J; Gelmon K; Whelan T; Strasser-Weippl K; Rubin S; Sturtz K; Wolff AC; Winer E; Hudis C; Stopeck A; Beck JT; Kaur JS; Whelan K; Tu D; Parulekar WR
    N Engl J Med; 2016 Jul; 375(3):209-19. PubMed ID: 27264120
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer.
    Danforth DN; Zujewski J; O'Shaughnessy J; Riseberg D; Steinberg SM; McAtee N; Noone M; Chow C; Chaudhry U; Lippman M; Jacobson J; Okunieff P; Cowan KH
    Ann Surg Oncol; 1998 Mar; 5(2):150-8. PubMed ID: 9527268
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.
    Volders JH; Haloua MH; Krekel NM; Negenborn VL; Barbé E; Sietses C; Jóźwiak K; Meijer S; van den Tol MP;
    Eur J Surg Oncol; 2016 Jul; 42(7):986-93. PubMed ID: 27211343
    [TBL] [Abstract][Full Text] [Related]  

  • 80. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.